ANN ARBOR, Mich., Feb. 27, 2011 /PRNewswire/ — With deep
regret, Adeona Pharmaceuticals, Inc. (Amex:
AEN), announced today the passing of its Senior Vice President
of Research & Development, David A. Newsome, M.D. Dr. Newsome
invented and developed ZincMonoCysteine and was the first person to
pioneer and demonstrate the benefits of oral high dose zinc therapy
in age-related macular degeneration, the leading cause of blindness
in older Americans. Oral high dose zinc containing nutritional
products now represent the standard of care for age-related macular
degeneration which affects over 10 million Americans.
During his career, Dr. Newsome spent over a decade in clinical
and laboratory research at the National Eye Institute, becoming the
Head of the Retinal Disease Section. As Associate Professor at the
Johns Hopkins Wilmer Eye Institute, Dr. Newsome combined teaching
and clinical work with his laboratory research. Dr. Newsome
continued his passion of teaching, patient care, clinical and
laboratory research as a full tenured Professor at Louisiana State
University Medical School, New Orleans. After teaching there, Dr.
Newsome formed his own surgical and medical retina disease private
practice, and continued to perform clinical and laboratory research
sponsored by the National Institutes of Health and private
foundation grants. After the devastation of Hurricane Katrina in
New Orleans, Dr. Newsome worked as a surgical ophthalmologist until
joining the management team at Adeona in 2006. He earned an M.D.
from Columbia University and a B.A. from Duke University, and
completed an ophthalmology residency and a fellowship in retinal
diseases and surgery at Harvard University. He also completed a
retinal fellowship at the Bascom Palmer Eye Institute, University
of Miami.
“On behalf of the Board of Directors and all of his colleagues
at Adeona, I would like to extend our hea
‘/>”/>
SOURCE